Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07614893 · ClinicalTrials.gov registry record · NA
Clinician Notification to Increase Aspirin Prophylaxis for Preeclampsia Prevention
A NA study, sponsored by Massachusetts General Hospital.
- Not yet
- Registry status
- NA
- Development phase
- 1,000
- Enrollment target
NCT07614893: Clinical Trial NA study, sponsored by Massachusetts General Hospital.
NCT07614893 is a NA study that has not yet begun recruiting, run by Massachusetts General Hospital. The registered enrollment target is 1,000 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07614893, a NA study, has not yet begun recruiting, sponsored by Massachusetts General Hospital.
- NOT YET RECRUITING
- Registry status
- NA
- Development phase
- 1,000 participants
- Enrollment target
Study Summary
Preeclampsia is a leading cause of maternal morbidity and mortality. Low-dose aspirin prophylaxis reduces preeclampsia risk among high-risk pregnant individuals but remains underused in routine clinical practice. This pragmatic cluster-randomized implementation trial will test whether clinician notification of elevated preeclampsia risk increases aspirin prophylaxis utilization among eligible pregnant individuals receiving outpatient obstetric care. Clusters will be randomized to clinician notification versus usual care. In the intervention arm, obstetric clinicians will receive notification that a patient is at elevated risk for preeclampsia and a recommendation to consider initiation of aspirin prophylaxis between 12 and 28 weeks' gestation, as clinically appropriate. The intervention does not assign participants to aspirin and does not require any study-mandated medication. All decisions regarding aspirin prophylaxis will remain at the discretion of the treating obstetric clinician and patient.
Interventions
- BEHAVIORAL Clinician notification of elevated preeclampsia risk
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,000 participants |
| Start Date | 2027-05 |
| Est. Completion | 2030-05 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07614893
The ClinicalTrials.gov registry entry for NCT07614893 describes a study currently listed as not yet recruiting, categorized as NA. The registered enrollment target is 1,000 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Massachusetts General Hospital, which has 2,032 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Clinician notification of elevated preeclampsia risk is the first listed.
NCT07614893 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07614893 about?
NCT07614893 is a clinical study titled "Clinician Notification to Increase Aspirin Prophylaxis for Preeclampsia Prevention". Preeclampsia is a leading cause of maternal morbidity and mortality. Low-dose aspirin prophylaxis reduces preeclampsia risk among high-risk pregnant individuals but remains underused in routine clinical practice. This pragmatic cluster-randomized implementation trial will test whether clinician noti...
What is the current status of trial NCT07614893?
This trial is currently not yet recruiting. It is a NA study. The enrollment target is 1,000 participants. The study started on 2027-05. Estimated completion is 2030-05.
What interventions are being tested in trial NCT07614893?
The interventions under investigation include: Clinician notification of elevated preeclampsia risk (BEHAVIORAL).
Who is sponsoring clinical trial NCT07614893?
This trial is sponsored by Massachusetts General Hospital, which has 2,032 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.